MEASUREMENT OF ANTIOXIDANT POWER OF MOUTHWASHES INDICATED IN STOMATITIS
Abstract
ABSTRACT
Objective: Hospital formulations containing allopurinol and rebamipide are used in the prophylactic and therapeutic management of stomatitis,
owing to their antioxidant powers. The objective of this study was to measure the antioxidant powers of Zyloric® tablets (allopurinol), Mucosta®
tablets (rebamipide), different hospital formulations indicated in the management of stomatitis (allopurinol and rebamipide mouthwashes), and
Azulene® 0.4% for Gargle (sodium azulene sulfonate).
Methods: We measured the antioxidant powers of Zyloric® and Mucosta® tablets, all hospital formulations indicated in the management of stomatitis
(allopurinol and rebamipide mouthwashes), and the widely used Azulene® 0.4% for Gargle by employing the biological antioxidant potential test. We
compared the efficacy of each of these drugs in the management of stomatitis.
Results: Azulene® 0.4% for Gargle was found to have stronger antioxidant power than Zyloric® (100 mg) and Mucosta® (100 mg) tablets dissolved in
water. The antioxidant power of the solvent used in hospital formulations was similar to that of the prepared hospital formulation. Antioxidant power
of the drugs themselves was not observed in both the allopurinol and rebamipide mouthwashes.
Conclusion: The antioxidant power of the drugs was not observed in both the allopurinol and rebamipide mouthwashes; therefore, hospital
formulations used as antioxidants were found to be less effective in the treatment of stomatitis. However, Azulene® 0.4% for Gargle was found to be
useful in the prophylactic and therapeutic management of stomatitis, owing to its antioxidant, and anti-inflammatory effects.
Keywords: Stomatitis, Bone alkaline phosphatase-test, Allopurinol mouthwash, Rebamipide mouthwash, Azulene® 0.4% for Gargle, Antioxidant power
Downloads
References
REFFERENCES
Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end – patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19(2):203-8.
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100 9 Suppl:1995-2025.
Douglas EP. Oral toxicity of chemotherapeutic agents. Semin Oncol 1992;19:478-91.
Peterson DE. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr 1990;61-71.
Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 1993;9(3):185-95.
Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 1990;29(2):171-3.
Porteder H, Rausch E, Kment G, Watzek G, Matejka M, Sinzinger H. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 1988;16(8):371-4.
Clark PI, Slevin ML. Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. Eur J Surg Oncol 1985;11(3):267-8.
Dozono H, Nakamura K, Motoya T, Nakamura S, Shinmura R, Miwa K, et al. Prevention of stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 1989;16(10):3449-51.
Elzawawy A. Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes. Oncology 1991;48(4):282-4.
Porta C, Moroni M, Nastasi G. Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 1994;17(3):246-7.
Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991;9(3):449-52.
Pourreau-Schneider N, Soudry M, Franquin JC, Zattara H, Martin PM, Ciais G, et al. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: A preliminary report. J Natl Cancer Inst 1992;84(5):358-9.
Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C, et al. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997;38(4):697-703.
Barasch A, Peterson DE, Tanzer JM, D’Ambrosio JA, Nuki K, Schubert MM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6.
Yasuda T, Chiba H, Satomi T, Matsuo A, Kaneko T, Miyamatsu H. A pilot study of rebamipide-gargle for chemoradiotherapy-induced mucositis in oral cancer patients. Gan To Kagaku Ryoho 2008;35:1157-61.
Tosaka C, Tajima H, Inoue T, Moya M, Kobayashi M, Miura K, et al. Investigation of how to prevent mucositis induced by chemoradiotherapy. Gan To Kagaku Ryoho 2011;38(10):1647-51.
Tsavaris NB, Komitsopoulou P, Tzannou I, Loucatou P. Allopurinol mouthwashes in methotrexate-induced stomatitis. Sel Cancer Ther 1991;7:113-7.
Panahi Y, Ala S, Saeedi M, Okhovatian A, Bazzaz N, Naghizadeh MM. Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. Eur J Cancer Care (Engl) 2010;19(3):308-12.
Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007 18;CD001973.
Seo JY, Kim H, Seo JT, Kim KH. Oxidative stress induced cytokine production in isolated rat pancreatic acinar cells: effects of small-molecule antioxidants. Pharmacology 2002;64(2):63-70.
Takano R, Hirano T, Nakata C, Kasashi K, Sugawara M, Kobayashi M, et al. Search for antioxidative compounds capable of preventing stomatitis induced by chemotherapy. Jpn J Pharm Health Care Sci 2009;35(4):247-53.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.